

Neothetics (NEOT : US\$10.05)

Neothetics jumps 37% in 2015, outperforming 89% of its global peers

Neothetics, Inc., jumped US\$2.69 (or 36.5%) year to date in 2015 to close at US\$10.05. The stock has a 6-month USD relative strength of 89 which means in USD terms it is outperforming 89% of its 45,045 global peers. A price rise combined with a high relative strength is a bullish signal. Compared with the NASDAQ-100 Index which has risen 2.4% YTD, this is a relative price increase of 34.1%. The average daily volume of 75,365 shares so far in 2015 was 1.2 times the average daily volume in 2014. In 2015 the market cap has jumped US\$36.6 million.

Fig 4: Shareholder Returns

Trailing quarter: The stock rose 35 times (53.8% of the time) and fell 30 times (46.2% of the time). The aggregate volume was 1.5 times average trading of 7.2 million shares. The value of US\$1,000 invested 3 months ago is US\$1,102 [vs 999 for the NASDAQ-100 Index] for a capital gain of US\$102.

PVUS\$1,000	Trailing Qtr	Trailing Yr	Trailing 3 Yrs
NEOT	US\$1,102		
Total Nasdaq Market	953	1,059	1,294
NASDAQ-100 Index	999	1,087	1,541

Figure 1: Stock Identifiers

PermID	1-4297632572
Central Index Key (CIK)	1618835
CUSIP	64066G101

Fig 2: Stock Summary

Sector	Total Nasdaq Market
Market Cap	US\$136.9 million
Shares Outstanding	13,620,148
Relative Strength (3 mo)	87

Fig 3: Rank in American Region out of 12,189 stocks

Description	Value	Rank	Quartile
MCap (US\$)	136.9M	4,632	Second
Total Assets (US\$)	76.9M	5,796	Second
Net Profit (US\$)	(10.8M)	9,253	Bottom
Return on Equity %	(16.6)	6,274	Third
Rel Strength 6 Mo (US\$)	92	994	Top

Price Volume Dynamics

Fig 5: Weekly Price Volume Dynamics (Last 12 Weeks)




Fig 6: Trailing 3 months

Turnover	US\$92.1 million
Volume	7,677,447
Volume Index (1 is avg)	1.5

Price Volume Dynamics

Fig 7: Trailing Price Change %

Price Change %	Quarter	Year	3 Years
NEOT	10.2		
Total Nasdaq Market	-4.7	5.93	29.42
NASDAQ-100 index	-0.4	8.72	54.11

Fig 8: Turnover Rate & Turnover Period




Fig 9: Month-on-Month Comparison (Trailing Month - ended 7th)

	07 Oct	04 Sep	07 Aug	07 Jul	05 Jun	07 May
Price 07 Oct (USD)	10.05	11.93	11.79	9.12	6.32	6.67
% Price Change	-15.3	-17.9	29.3	38	-6	-20.4
Avg Daily Volume	80,045	79,872	80,823	63,203	50,677	51,021
VWP (USD)	12.09	11	10.2	7.59	7.36	7.62
Price Range (USD)	7.62 - 12.99	10.8 - 15.05	8.58 - 15.05	6.25 - 9.98	5.92 - 6.72	6.19 - 9.05
Relative Price Change %	-18.8	-9.5	27.2	39	-7.5	-21.7
Volatility %	70.5	39.4	75.4	59.7	13.5	46.2

Price Volume Dynamics (continued)

Fig 10: Price Volume Trend: Trailing Quarter



Neothetics hit a 3-month high of US\$15 on Aug 04 and a 3-month low of US\$8 on Oct 02.


Ranking

Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

Ranking (continued)

Fig 11: Slipping Relative Strength




Institutional Holders Buying and Selling

Fig 12: List of Top 10 Institutional Holdings

Name of Shareholder	No. of Shares	% Held	Value USD
Clifton Park Capital Management LLC	821,566	6.03	8.3 M
Piper Jaffray & Co.	303,420	2.23	3 M
Federated Investors Inc, PA	275,400	2.02	2.8 M
Dafna Capital Management LLC	186,807	1.37	1.9 M
Lombard Odier Asset Management (Usa) Corp	179,300	1.32	1.8 M
Nicholas Investment Partners Lp	118,012	0.87	1.2 M
Alyeska Investment Group L.P.	102,724	0.75	1 M
UBS Oconnor LLC	66,698	0.49	670,315
Goldman Sachs Group Inc	56,782	0.42	570,659
Vanguard Group Inc	50,100	0.37	503,505
Total	2,160,809	15.86	

Fig 13: Top 17 Institutional Holdings as % of total



Institutional Shareholders Summary

The following transactions were reported to the SEC for the quarter ended 30 June 2015 by institutions holding more than \$100m of total investments.

30 June 2015 share price of Neothetics: US\$8.88
 2 Institutions bought 5,421 shares valued at US\$48,138.
 3 Institutions sold 49,100 shares valued at US\$436,008.
 Net reported selling by 5 institutions in the quarter: US\$387,870.

Institutional Shareholders Selling

Top 2 Holders

Dafna Capital Management LLC sells

Neothetics (NASDAQ:NEOT) institutional shareholder Dafna Capital Management LLC sold 2,620 shares in the quarter ended Jun 30, 2015. Dafna Capital Management LLC now holds 184,187 shares worth USD2.3 million.

UBS Oconnor LLC sells

Neothetics (NASDAQ:NEOT) institutional shareholder UBS Oconnor LLC sold 45,000 shares in the quarter ended Jun 30, 2015. UBS Oconnor LLC now holds 21,698 shares or 1.22% worth USD254,301.

Company Overview and Regulatory Announcements

Activities

Neothetics, Inc. is a clinical-stage pharmaceutical company. The Company develops therapeutics for the aesthetic market. The Company is focused on localized fat reduction and body contouring.

Further details can be found at
<http://www.neothetics.com>.

Issued Capital

Based on 13,620,148 issued equity shares the market capitalisation is US\$136.9 million.

Fig 14: Reported Selling

Name	Date	Transaction Type	No. of Shares	Price, USD	Value, USD
Kemmerer Christopher	Sep 18, 2015	Sold	1,000	12.2	12,195
Knudson Susan A.	Sep 01, 2015	Sold	3,000	11.33	33,990
Kemmerer Christopher	Aug 07, 2015	Sold	1,000	12.88	12,880

Fig 15: Reported Trades



8-K people news

September 29: Neothetics appoints Hani Zeini as director 30 September 2015

Neothetics has appointed Hani Zeini as Director. The appointment takes effect from Sep 23, 2015.

June 17: Neothetics Elects 2 Directors

Neothetics (NEOT) held its Annual General Meeting on June 16, 2015. According to an SEC filing under Section 8-K Item 5.07 the following directors were elected:

Daniel S. Janney
Maxim Gorbachev

8-K other news

August 13: Neothetics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000156459015007165_0001564590-15-007165.txt

Source: Securities and Exchange Commission

May 14: Neothetics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000156459015004238_0001564590-15-004238.txt

Source: Securities and Exchange Commission

March 26: Neothetics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000156459015001989_0001564590-15-001989.txt

Source: Securities and Exchange Commission

January 21: Neothetics: Entry into a Material Definitive Agreement

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000119312515016052_0001193125-15-016052.txt

Source: Securities and Exchange Commission

Meetings

June 09: Neothetics announces AGM

Neothetics has announced its Annual General Meeting will take place on June 16, 2015.

Regulatory Announcements (continued)

Intellectual Property

October 06: Neothetics Announces Issuance By Uspto Of Additional Patent Directed To Lipo-202 Lead Clinical Asset

SAN DIEGO, Oct. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance of U.S. Patent No. 9,132,084 by the United States Patent and Trademark Office (USPTO). This marks issuance of the company's third United States patent in its portfolio that is directed to Neothetics' lead asset, LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. This particular patent is directed to formulations and methods for reducing adipose tissue using LIPO-202. George Mahaffey, Neothetics' president and chief executive officer, stated: "We are pleased to have received issuance of this most recent patent from the USPTO, which further strengthens our robust intellectual property portfolio protecting our lead body contouring product candidate, LIPO-202, which is currently in pivotal Phase 3 trials."

About LIPO-202

Source: <http://www.nasdaq.com/aspx/stockmarketnewsstoryprint.aspx?storyid=neothetics-announces-issuance-by-uspto-of-additional-patent-directed-to-lipo202-lead-clinical-asset-20151006-00375> Nasdaq Stock Exchange

[For more details click here.](#)

August 06: Neothetics Announces Reaffirmation Of Patents And Termination Of Reexamination Challenge By United States Patent And Trademark Office

[News Story] SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the reaffirmation of all claims of two of its issued patents by the United States Patent and Trademark Office (USPTO) and termination of the reexamination challenges that were initiated by a third party.

[For more details click here.](#)

Performance

August 13: Neothetics Reports Second Quarter 2015 Financial Results

[News Story] SAN DIEGO, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the second quarter 2015.

"We remain on track for reporting topline results from our pivotal U.S. Phase 3 trials later this year," said George Mahaffey, president and chief executive officer of Neothetics. "There is clearly high demand for new, safe and effective FDA-approved drug options in the rapidly growing non-invasive body contouring market. If approved, LIPO-202 will be the first drug approved for reduction of central abdominal bulging."

Second Quarter 2015 Highlights

[Read more...](http://www.nasdaq.com/press-release/neothetics-reports-second-quarter-2015-financial-results-20150813-00314)

Source: Nasdaq Stock Exchange

[For more details click here.](#)

August 06: Neothetics To Release Second Quarter 2015 Financial Results

[News Story] SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its second quarter 2015 financial results before the market opens on Thursday, August 13, 2015.

To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.com and register for email alerts.

About Neothetics, Inc.

[Read more...](http://www.nasdaq.com/press-release/neothetics-to-release-second-quarter-2015-financial-results-20150806-00529)

Source: Nasdaq Stock Exchange

[For more details click here.](#)

Press Releases

October 01: Neothetics Initiates Study To Evaluate The Safety Of Lipo-202 For Body Contouring In Obese Subjects

SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of the safety study, LIPO-202-CL-21, of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

[For more details click here.](#)

Regulatory Announcements (continued)

September 21: Neothetics To Present At The Oc Summit On Aesthetics And Dermatology

SAN DIEGO, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey, president and chief executive officer, was selected to present at the Orange County Summit on Aesthetics and Dermatology on September 26th at 4:30PM PT.

[For more details click here.](#)

September 08: Neothetics Announces Last Patient Enrolled In Lipo-202 Pivotal Phase 3 Clinical Trials For Reduction Of Subcutaneous Abdominal Fat

SAN DIEGO, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced completion of enrollment for its two pivotal U.S. Phase 3 trials titled AbCONTOUR1 and AbCONTOUR2. The trials are evaluating LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

[For more details click here.](#)

June 30: Neothetics Initiates Study To Evaluate The Post-treatment Safety And Duration Of Clinical Effect Of Lipo-202 For Body Contouring

[News Story] SAN DIEGO, June 30, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of the post-treatment safety and duration of effect study, LIPO-202-CL-23, of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

[For more details click here.](#)

June 18: Neothetics director awarded Stock Options

Neothetics (NASDAQ:NEOT) director Kamdar Kim P., has been awarded Stock Options on 36,390 shares at an exercise price of US\$6.29. The transaction date was June 16, 2015. The shares last traded at US\$7.87, hitting a three-month high on the day.

June 17: Neothetics: Submission of Matters to a Vote of Security Holders

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1618835_000156459015005118_0001564590-15-005118.txt

Source: Securities and Exchange Commission

May 14: Neothetics: Neothetics Reports First Quarter 2015 Financial Results

[News Story] SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the first quarter 2015.

First Quarter 2015 and Recent Corporate Highlights
"We continue to advance development of our product candidate, LIPO-202, for the reduction of central abdominal bulging," said George Mahaffey, president and chief executive officer of Neothetics. "We are focused on providing a non-invasive, safe and effective alternative for the high-growth body contouring market."

[Read more...](http://www.nasdaq.com/press-release/neothetics-reports-first-quarter-2015-financial-results-20150514-00360)

Source: Nasdaq Stock Exchange

[For more details click here.](#)

May 07: Neothetics to Release First Quarter 2015 Financial Results, Host Annual Stockholder Meeting

SAN DIEGO, May 7, 2015 Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that it will release its first quarter 2015 financial results before the market opens on Thursday, May 14, 2015. Neothetics also invites stockholders to attend its 2015 Annual Meeting, which will be held on June 16, 2015, at 9:00 a.m.

[For more details click here.](#)

April 13: Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat

[News Story] SAN DIEGO, April 13, 2015 -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of two pivotal U.S. Phase 3 trials titled AbCONTOUR1 and AbCONTOUR2 of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

[For more details click here.](#)

April 08: Events Calendar: Neothetics to Present at Needham & Company's 14th Annual Healthcare Conference

SAN DIEGO, April 8, 2015 -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey, president and chief executive officer, will present at Needham & Company's 14th Annual Healthcare Conference in New York City on Wednesday, April 15th at 11:20 a.m.

[For more details click here.](#)

Regulatory Announcements (continued)

March 26: Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results

[News Story]

Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the fourth quarter and year ended December 31, 2014.

2014 Key Corporate Highlights

On November 20, 2014, completed an initial public offering of 4,650,000 common shares on NASDAQ resulting in \$65.1 million in gross proceeds, which exceeded the initial range of estimated proceeds.

[For more details click here.](#)

March 23: Neothetics Initiates Study to Evaluate Safety of Retreatment With LIPO-202 for Body Contouring

[News Story] SAN DIEGO, March 23, 2015 (GLOBE NEWSWIRE)

-- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced it has initiated an open-label study to evaluate the safety of multiple courses of treatment of LIPO-202 (salmeterol xinafoate for injection) for the reduction of central abdominal bulging.

[For more details click here.](#)

March 04: Events Calendar: Neothetics to Present at the 27th Annual Roth Conference

SAN DIEGO, March 4, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey, president and chief executive officer, will present at the 27th Annual ROTH Conference, on Wednesday, March 11th at 12:00 p.m.

[For more details click here.](#)

February 25: Neothetics: WaferGen Bio-systems Announces Positive Results of a Single Cell Study Utilizing Its SmartChip(TM) Technology Conducted in Collaboration With the Broad Institute

[News Story] FREMONT, Calif., Feb. 25, 2015 WaferGen Bio-systems, (Nasdaq:WGBS) announced today that it has produced positive results in a study aimed at validating the utility of its SmartChipTM technology for isolating and studying single cells via Next-Generation Sequencing (NGS). The study was conducted in collaboration with the Broad Institute, and the findings will be presented at the 2015 Advances in Genome Biology & Technology (AGBT) meeting to be held February 25-28 in Marco Island, Florida.

[For more details click here.](#)

February 25: Events Calendar: Neothetics to Present at Cowen and Company 35th Annual Health Care Conference

[News Story] SAN DIEGO, Feb. 25, 2015 Neothetics, Inc.

(Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced that George Mahaffey, president and chief executive officer, will present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3rd at 1:30 p.m.

[For more details click here.](#)

February 12: Leading Aesthetic Physicians Join Neothetics' Newly Formed Corporate Advisory Board

[News Story] SAN DIEGO, Feb. 12, 2015 - Neothetics, Inc.

(Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the creation of a corporate advisory board composed of leading plastic surgeons, dermatologists and other physicians.

February 12: Neothetics Insider awarded Stock Options

Neothetics (NASDAQ:NEOT) Insider Kemmerer Christopher, has been awarded Stock Options on 42,350 shares at an exercise price of US\$6.79. The transaction date was February 10, 2015. The shares last traded at US\$6.71.

February 12: Neothetics Insider awarded Stock Options

Neothetics (NASDAQ:NEOT) Insider Krochmal Lincoln, has been awarded Stock Options on 16,288 shares at an exercise price of US\$6.79. The transaction date was February 10, 2015. The shares last traded at US\$6.71.

February 12: Neothetics Insider awarded Stock Options

Neothetics (NASDAQ:NEOT) Insider Locke Kenneth W, has been awarded Stock Options on 16,288 shares at an exercise price of US\$6.79. The transaction date was February 10, 2015. The shares last traded at US\$6.71.

February 12: Neothetics Insider awarded Stock Options


Neothetics (NASDAQ:NEOT) Insider Knudson Susan A., has been awarded Stock Options on 45,607 shares at an exercise price of US\$6.79. The transaction date was February 10, 2015. The shares last traded at US\$6.71.

Board and Management & creation of shareholder value



George Mahaffey
CEO & President & Director

Mr. Mahaffey has 24 years of pharmaceutical and biotechnology industry experience. Most recently, he served as CEO of Peplin, Inc. after the dermatology company's acquisition by LEO Pharma A/S in 2014; he was instrumental in this \$287.5M transaction. Prior to the acquisition, he served as Peplin's Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for Co Therix, Inc. where he led the corporate commercialization and successful launch of Ventavis (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. for \$420M in 2006. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson for \$2.4B in 2003) where he led the launch of Natrecor (nesiritide) to treat acutely decompensated congestive heart failure that proved to be one of the most successful launches of any acute care cardiovascular product to date. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. for \$700M in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey earned a Bachelor of Science degree in Chemical Engineering from the University of Delaware and an MBA from the University of South Florida.



Susan Knudson
CFO

Susan A. Knudson has served as Chief Financial Officer of Neothetics since July 2014 and Vice President of Finance and Administration since February 2009. Ms. Knudson brings over 18 years of financial, venture capital, corporate strategy, and operations experience in the life sciences industry to Neothetics. She has worked in both public and private companies, with operations ranging from domestic to international. Prior to joining Neothetics, Susan served as the Sr. Director of Finance and Administration at Avera Pharmaceuticals, where she spearheaded the Company's financing strategy, raising over \$90 million in venture capital, and was an integral part of the in-licensing of the Company's lead drug candidates from large, multinational pharmaceutical companies. From October 2000 through April 2002, Susan served as Director of Finance and Administration at MD Edge. Ms. Knudson has also held senior positions at Isis Pharmaceuticals and CombiChem. While at CombiChem, she contributed to the Company's successful initial public offering and, later, sale to DuPont. Ms. Knudson holds a B.A. in Accounting from the University of San Diego.

Kim P. Kamdar Director

Kim P. Kamdar, Ph.D. has served as a member of our board of directors since April 2011. Dr. Kamdar is a managing member of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005. Prior to joining Domain, Dr. Kamdar served as a Kauffman Fellow with MPM Capital. Prior to joining MPM Capital, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology. Dr. Kamdar currently serves on the board of directors of several private companies, including Ariosa Diagnostics, Epic Sciences, Inc., Obalon Therapeutics, ROX Medical, Sera Prognostics, Syndax Pharmaceuticals and Tragara Pharmaceuticals. Dr. Kamdar received her B.A. in genetics and cell biology from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.


Board and Management & creation of shareholder value (continued)

Hani Zeini Director

Mr. Hani Zeini is Director of Neothetics, Inc. Mr. Zeini brings extensive leadership and commercialization experience to Neothetics. He has over 27 years of relevant healthcare experience in pharmaceuticals and medical device industries, and is a 14-year veteran in the aesthetics and plastic surgery market. Mr. Zeini founded and has been the President and Chief Executive Officer of Sientra, Inc since its inception in 2006. Previously, he served as Executive Vice President of Inamed Aesthetics (now Allergan Medical) responsible for both the breast aesthetics and facial aesthetics businesses. Prior to joining Inamed, Mr. Zeini was the Chief Operating Officer at Acurian, Inc., a development stage venture capital-backed clinical trials company. Before Acurian, he held the position of President and Chief Executive Officer at Pharmsmarket.com, an Internet-based healthcare marketplace. Mr. Zeini has been deeply involved in developing the aesthetics and plastic surgery market over the past decade. He pioneered the concept of the Plastic Surgery Ecosystem(TradeMark) and served twice on the American Society of Plastic Surgeons Annual Meeting Committee as the industry representative. He also served on the Industry Relations Council for the American Society for Aesthetic Plastic Surgery. Mr. Zeini has been a long-time advocate and a driving force for the adoption of evidence-based outcomes in aesthetic surgery. Mr. Zeini started his career at the Dupont Pharmaceuticals Company, where he spent over 12 years in a variety of positions culminating with his role as Senior Vice President, Global Health Systems. Mr. Zeini holds a BS degree in Electrical and Computer Engineering from the University of Miami in Coral Gables, Florida. In 2003, Mr. Zeini completed the Stanford Executive Program at Stanford University, Graduate School of Business.

Creation of shareholder value in Neothetics:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of September 23, 2015 at close price of US\$12.28 is US\$818, for a capital loss of US\$182.



Kenneth W. Locke Chief Scientific Officer

Kenneth W. Locke serves as our Chief Scientific Officer with over 24 years of experience in the pharmaceutical industry. Concurrent to his service at Neothetics in May 2008, Dr. Locke progressively held the positions of Vice President, Research, Senior Vice President, Development Operations & Drug Discovery, Senior Vice President, Portfolio Management, Chief Business Officer and Chief Scientific Officer with MediciNova, Inc. starting in September 2000. Prior to joining MediciNova, he held the position of Vice President of Research at Tanabe Research Laboratories U.S.A., Inc. From July 2000 to October 2002 Dr. Locke joined Interneuron Pharmaceuticals, Inc. in 1989 as the Manager of Behavioral Neuroscience, taking on positions of increasing responsibility over the next 11 years. Earlier in his career, Dr. Locke headed laboratories for analgesic and anti-inflammatory drug research as well as Alzheimer's disease drug research at Hoechst-Roussel Pharmaceuticals, Inc. Dr. Locke earned a B.A. in Chemistry and French from Franklin and Marshall College and a M.S. and a Ph.D. in Pharmacology from the Emory University School of Medicine.

Board and Management & creation of shareholder value (continued)



Lincoln Krochmal
Chief Medical Officer

Dr. Krochmal is a Board certified Dermatologist with 30 plus years experience in the pharmaceutical and consumer goods industries focusing on the development of new products both locally and globally. His most recent role was as CEO & President of Excaliard Pharmaceuticals. He successfully led the Excaliard team in generating positive Proof of Concept data for their lead compound as a treatment for reducing skin scarring. This data subsequently resulted in Pfizer acquiring Excaliard for a total value close to \$500m. Prior to that he was Executive Vice President, Research and Product Development for Connetics Corporation, a specialty dermatology company headquartered in Palo Alto. Following 3 and a half years with Connetics, Dr Krochmal formed his own consultant business providing strategic guidance and technical assistance to the pharmaceutical and aesthetics industries. Dr. Krochmal began his career in the pharmaceutical industry following 8 years of private dermatology practice by joining Westwood Pharmaceuticals (the dermatology subsidiary of Bristol-Myers Squibb) in 1983 as Director of Clinical Research. Over the subsequent 10 years, he held several roles of increasing responsibility including VP, Dermatology Research and Development, overseeing both preclinical and clinical disciplines, and VP, Worldwide Medical Development, providing global support in Biostatistics & Data Management, Human Pharmacology, Drug Safety, Medical Communications and Clinical Study Field Operations to all 5 Therapeutic Areas of Bristol-Myers Squibb. In 1993, Dr. Krochmal joined Unilever PLC, where he spent 10 years in various senior management positions directing the worldwide development of numerous consumer products for the Home and Personal Care Division.

Chris Kemmerer Vice President-Pharmaceutical Development and Manufacturing

Chris Kemmerer, Ph.D. serves as our Vice President of Pharmaceutical Development and Manufacturing with 20 years of experience in the pharmaceutical industry. In this capacity, Chris is primarily responsible for developing our drug product formulations and providing pre-clinical and clinical supplies. Prior to joining Neothetics, Chris held the position of Director of Pharmaceutical Development at Avera Pharmaceuticals developing controlled release formulations and formulations of poorly water-soluble drug candidates. Prior to Avera, Chris held positions of increasing responsibility at Pfizer, Inc, La Jolla, CA and was responsible for process and development activities for Diabetes drug candidates. Prior to joining Pfizer, Inc. Chris held positions across numerous functional areas of drug development at Merck & Company in West Point, PA, including in process and formulation development, scale-up, and manufacturing roles. In these capacities, Chris was an important contributor to the development of Emend and oversaw the manufacturing of over 20 commercial drug products including Pepcid, Prilosec, and Nexium. Chris earned a B.S. in Chemistry from Pennsylvania State University and a Ph.D. in Pharmaceuticals Sciences from Temple University in Philadelphia, PA.

Glossary

Capital Gain/Loss from n Years Ago to n-1 Years Ago:

Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)

Relative Price Change (Fig 9):

Today's Relative price change with respect to Benchmark Index

Return on Equity (Shareholders' Funds) (Fig 3):

Net Profit/Net Assets (%)

Turnover Period (Fig 8):

Time Period required for trading all Outstanding Shares

Volatility (Fig 9):

Highest Price minus Lowest Price/Lowest Price (%)

Volume Weighted Price (VWP) (Fig 9):

The Volume Weighted Price (VWP) is the summation of turnover divided by total volume in the same period.

PVUS\$1000 (Fig 4):

Present value of US\$1000 invested 1 year/'n' years ago

Relative Strength (n-th Period) (Fig 2, 11, 3):

Price close today/Price close 'n' periods ago, then ranked by percentile within the entire market.

Turnover (Fig 6):

Last Price * Volume

Turnover Rate (Fig 8):

US Dollar value of annual trading volume as a percentage of market capitalisation

Volume Index (VI) (Fig 6):

Number of shares traded in the period/Average number of shares traded for the period

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

For further details on definitions and quotations from investing legends, [Click here](#)

For any enquiries, please email: feedback@buysellsignals.com

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756), who provide round the clock data on every stock and sector. BuySellSignals is not a broker, and does not have an executing, corporate advisory or investment banking function. BuySellSignals, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.